Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes

Bibliography

• Ryden L, Standl E, Bartnik M, Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
   PubMed Web of Science ®Google Scholar
• Buse JB, Ginsberg HN, Bakris GL, Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162-72
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
   PubMed Web of Science ®Google Scholar
• Association AD. Standards of medical care in diabetes – 2012. Diabetes Care 2012;35(Suppl 1):S11-63
   Google Scholar
• Reiner Z, Catapano AL, De Backer G, ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
   PubMed Web of Science ®Google Scholar
• Kearney PM, Blackwell L, Collins R, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25
   PubMed Web of Science ®Google Scholar
• Lea AP, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997;53:828-47
   PubMed Web of Science ®Google Scholar
• Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001;61:1835-81
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
   PubMed Web of Science ®Google Scholar
• Knopp RH, d'Emden M, Smilde JG, Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-85
   PubMed Web of Science ®Google Scholar
• Sarwar N, Gao P, Seshasai SR, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-22
   PubMed Web of Science ®Google Scholar
• Ceriello A, Hanefeld M, Leiter L, Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164:2090-5
   PubMed Web of Science ®Google Scholar
• Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation 2011;123:342-8
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
   PubMed Web of Science ®Google Scholar
• Seaquist ER, Miller ME, Bonds DE, The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care 2012;35:409-14
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13:81-99
   PubMed Web of Science ®Google Scholar
• Gallwitz B, Haring HU. Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2010;12:1-11
   PubMed Web of Science ®Google Scholar
• Burge MR, Sood V, Sobhy TA, Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review. Diabetes Obes Metab 1999;1:199-206
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents – an update. Drug Saf 2005;28:601-31
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-88
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cytochrome P450-mediated cardiovascular drug interactions. Expert Opin Drug Metab Toxicol 2011;7:1065-82
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Sitagliptin. Drugs 2007;67:587-97
   PubMed Web of Science ®Google Scholar
• Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:489-512
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opin Drug Metab Toxicol 2010;6:1265-76
   PubMed Web of Science ®Google Scholar
• Chwieduk CM. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. Drugs 2011;71:349-61
   PubMed Web of Science ®Google Scholar
• Hutchins V, Zhang B, Fleurence RL, A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011;27:1157-68
   PubMed Web of Science ®Google Scholar
• Rozenfeld Y, Hunt JS, Plauschinat C, Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008;14:71-5
   PubMed Web of Science ®Google Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009;11:527-33
   PubMed Web of Science ®Google Scholar
• Curran MP. Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. Drugs 2010;70:191-213
   PubMed Web of Science ®Google Scholar
• Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141-60
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58
   PubMed Web of Science ®Google Scholar
• Bergman A, Ebel D, Liu F, Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007;28:315-22
   PubMed Web of Science ®Google Scholar
• Vincent SH, Reed JR, Bergman AJ, Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007;35:533-8
   PubMed Web of Science ®Google Scholar
• Chu XY, Bleasby K, Yabut J, Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007;321:673-83
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Cote J, Yi B, Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862-4
   PubMed Web of Science ®Google Scholar
• Chung M, Calcagni A, Glue P, Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol 2006;46:1030-7
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Cote J, Maes A, Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol 2009;49:483-8
   PubMed Web of Science ®Google Scholar
• KP A, Meda VS, Raj Kucherlapati VSP, Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. Eur J Clin Pharmacol 2012;68:709-14
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BH, Franken AA, Vincent HH. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study. J Intern Med 2005;257:531-9
   PubMed Web of Science ®Google Scholar
• Group DALIDS. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001;24:1335-41
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
   PubMed Web of Science ®Google Scholar
• Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2011;215:1-8
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Liamis GL, Milionis HJ, Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 2010;8:612-31
   PubMed Web of Science ®Google Scholar
• Baker WL, Talati R, White CM, Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98-107
   PubMed Web of Science ®Google Scholar
• Koh KK, Quon MJ, Han SH, Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010;55:1209-16
   PubMed Web of Science ®Google Scholar
• Simsek S, Schalkwijk CG, Wolffenbuttel BH. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes-the CORALL study. Diabet Med 2012;29:628-31
   PubMed Web of Science ®Google Scholar
• Waters DD, Ho JE, DeMicco DA, Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57:1535-45
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul S, Farmer A, Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia 2009;52:50-9
   PubMed Web of Science ®Google Scholar
• Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. FDA U.S. Drug and Food Administration. 2012. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm [Last accessed 16 April 2012]
   Google Scholar
• Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes : a critical review of head-to-head trials. Diabetes Metab 2012;38:89-101
   PubMed Web of Science ®Google Scholar
• Monami M, Lamanna C, Desideri CM, DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012;29:14-25
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71:1441-67
   PubMed Web of Science ®Google Scholar
• Tremblay AJ, Lamarche B, Deacon CF, Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:366-73
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Erqou S, Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010;170:1024-31
   PubMed Web of Science ®Google Scholar
• Taylor F, Ward K, Moore TH, Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011;1:CD004816
   Google Scholar
• van Leuven SI, Kastelein JJ. Atorvastatin. Expert Opin Pharmacother 2005;6:1191-203
   PubMed Web of Science ®Google Scholar
• Croom KF, Plosker GL. Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs 2005;65:137-52
   PubMed Web of Science ®Google Scholar
• de Lorgeril M, Hamazaki T, Kostucki W, Is the use of cholesterol-lowering drugs for the prevention of cardiovascular complications in type 2 diabetics evidence-based? A systematic review. Rev Recent Clin Trials 2012;7:150-7
   PubMedGoogle Scholar
• Anagnostis P, Athyros VG, Adamidou F, Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011;13:302-12
   PubMed Web of Science ®Google Scholar
• Monami M, Iacomelli I, Marchionni N, Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224-35
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Engel SS, Round E, Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7
   PubMed Web of Science ®Google Scholar
• Murohara T. Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection. J Am Coll Cardiol 2012;59:277-9
   PubMed Web of Science ®Google Scholar
• (TECOS). Scos. TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control. ClinicalTrials.gov Identifier. NCT00790205 Available from: http://wwwclinicaltrialsgov/ct2/show/NCT00790205?term=TECOS&rank=1 published on line; doi
   Google Scholar
• Gaede P, Vedel P, Larsen N, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Karagiannis A, Atorvastatin: safety and tolerability. Expert Opin Drug Saf 2010;9:667-74
   PubMed Web of Science ®Google Scholar
• Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther 2001;15:211-18
   PubMed Web of Science ®Google Scholar
• Waeber B, Buclin T, Grouzmann E. Angioedema during ACE and DPP-4 inhibition. Rev Med Suisse 2010;6:28-31
   PubMedGoogle Scholar
• Engel SS, Williams-Herman DE, Golm GT, Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-90
   PubMed Web of Science ®Google Scholar
• Bhome R, Penn H. Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. Diabet Med 2012;29:693-4
   PubMed Web of Science ®Google Scholar
• Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 2008;25:1229-30
   PubMed Web of Science ®Google Scholar
• DiGregorio RV, Pasikhova Y. Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. Pharmacotherapy 2009;29:352-6
   PubMed Web of Science ®Google Scholar
• Boucher BJ. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone? Diabet Med 2009;26:192-3
   PubMed Web of Science ®Google Scholar
• Chan JC, Scott R, Arjona Ferreira JC, Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55
   PubMed Web of Science ®Google Scholar
• Pendergrass M, Fenton C, Haffner SM, Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab 2012, published on line 2012/01/25; doi: 10.1111/j.1463-1326.2012.01567.x.
   PubMed Web of Science ®Google Scholar